Industry Trend Analysis - Opportunities Remain In MS Market - JAN 2018


BMI View: Presentations at MSParis2017 demonstrated the avenues pharmaceutical companies are pursuing to achieve a share of the lucrative, but also crowded multiple sclerosis (MS) drugs market. Whilst B-cell depletion is an efficacious new weapon, other new products are targeting simplified dosing, improved safety and more favourable tolerability compared to established treatments, and Celgene's ozanimod is a likely blockbuster drug of the future . P aediatric and secondary progressive MS represent area s of unmet need and are being pursued by Novartis, which is facing the arrival of generic Gilenya.

The multiple sclerosis (MS) drugs market is crowded and increasingly competitive, yet opportunities remain for innovative new products and the pipeline continues to attract investment. Remaining areas of unmet need include secondary progressive MS (SPMS), paediatric MS, neuroprotection and repair, predicting who would benefit from specific treatments, reducing side effects of medications and improving medication adherence. Data presented at the recent 7th Joint ECTRIMS-ACTRIMS Meeting (MSParis2017) in Paris, France, demonstrated the various approaches pharmaceutical companies are taking in order to gain a share of this market.

B-Cell Depletion: A New Weapon In MS

Ozanimod To Build Blockbuster Sales As Gilenya Declines
Forecast Annual Product Sales (USDmn)
e=estimate. Source: Bloomberg, BMI

This article is part of our Western Europe coverage. To access this article subscribe now or sign up for free trial